ERBB2 and cancer: Our results suggest that immuno-PET imaging using 89Zr-DFO-pertuzumab could be used to determine the target expression level and monitor the therapeutic response in HER2-positive cancer under various trastuzumab-based or HER2-targeted therapeutic regimens.